To contribute to the elimination of schistosomiasis by addressing the medical need of infected preschool-aged children, including infants and toddlers, a group currently devoid of a suitable treatment.



To develop and provide a suitable pediatric praziquantel formulation with acceptable palatability, proven efficacy and safety for treating schistosomiasis in preschool-aged children.



To make a meaningful contribution to tropical medicine and health innovation in endemic countries. We aim to provide scientific evidence and potentially trigger the creation of policies for prevention and treatment of schistosomiasis in children.


Pediatric Praziquantel Formulation

A new child-appropriate praziquantel formulation is essential for treating children under 6 years of age. The formulation consists of small, orodispersible tablets with an (improved) acceptable taste.


Contact us

Thank you for your interest in learning more about the Pediatric Praziquantel Consortium.

We care about your questions and concerns.


Pediatric Praziquantel Consortium represented at PIDE meeting in Brazil

Last month, Consortium partner Farmanguinhos participated in the 15th Meeting of the Integrated Program for Schistosomiasis (PIDE), held in Belo Horizonte, Brazil. Read more

SASOG2016 Meeting in South Africa

Consortium to join SASOG2016 Meeting in South Africa. Read more

Download our Factsheet here

Video credit: Shelly Xie